Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure - PubMed
5 hours ago
- #treatment resistance
- #anti-PD-1 therapy
- #cutaneous squamous-cell carcinoma
- Anti-PD-1 therapy is the main treatment for advanced cutaneous squamous-cell carcinoma (CSCC), but many patients experience treatment failure.
- A retrospective study of 238 CSCC patients treated with anti-PD-1 therapy found that 72 patients (median age 72) exhibited treatment failure.
- Progression patterns post-anti-PD-1 failure were local (21%), locoregional (37%), or distant metastatic (42%).
- Primary resistance was observed in 62.5% of patients, while 37.5% developed secondary resistance. Primary resistance was linked to lower tumor mutational burden (TMB).
- Subsequent treatments included cetuximab-based therapy and local treatments (31% each), with partial responses in 25% and stable disease in 6% of patients.
- Median overall survival (OS) was 44.1 months, and median event-free survival (EFS2) was 7.1 months post-subsequent treatment.
- CSCC-specific mortality was 50% at 5 years, and prior chemotherapy was associated with poorer OS.
- The study highlights the need for better treatment strategies post-anti-PD-1 failure in CSCC patients.